{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:47:47Z","timestamp":1777420067247,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:00:00Z","timestamp":1369699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To determine whether concomitant administration of zoster vaccine and polysaccharide pneumococcal-23 vaccine (PPV23) provides sufficient protection against herpes zoster infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>Literature was retrieved through the Centers for Disease Control and Prevention (CDC) website, PubMed (inception-February 2013), and Scopus (inception-February 2013) using the key words herpes zoster, pneumococcal, vaccine, concomitant, simultaneous administration, Pneumovax, Zostavax, and barriers. In addition, reference citations from publications were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION<\/jats:title>\n                    <jats:p>All English-language articles identified from the data sources were evaluated. Two studies evaluating concomitant and nonconcomitant administration of zoster vaccine and PPV23 were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>Current product labeling recommends a 4-week interval between zoster vaccine and PPV23 administration; however, the Food and Drug Administration (FDA) and the CDC promote concomitant administration to prevent a missed opportunity to vaccinate. This has caused confusion among health care professionals regarding the appropriate timing of these vaccines. A randomized trial that evaluated the immunogenicity of zoster vaccine and PPV23 given together versus separated by at least 4 weeks demonstrated that the varicella zoster virus (VZV) antibody levels of concomitant versus nonconcomitant vaccination groups did not meet noninferiority requirements. However, a large retrospective cohort trial that compared the incidence of herpes zoster infections following concomitant versus nonconcomitant administration of PPV23 and zoster vaccine did not find a statistically significant between-group difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Concomitant administration of zoster vaccine and PPV23 is advocated by the CDC and FDA to improve immunization rates among vaccine-eligible individuals. Since there is no direct evidence that simultaneous administration of zoster vaccine and PPV23 puts patients at increased risk of developing herpes zoster, the vaccines should be given during the same office visit to avoid a missed opportunity to vaccinate against 2 serious diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1r742","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T00:53:07Z","timestamp":1369788787000},"page":"1064-1068","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Concomitant Administration of Pneumococcal-23 and Zoster Vaccines Provides Adequate Herpes Zoster Coverage"],"prefix":"10.1177","volume":"47","author":[{"given":"Marcia J","family":"Wyman","sequence":"first","affiliation":[{"name":"Marcia J Wyman PharmD BCPS, Drug Information Pharmacist, Department of Pharmacy, Drug Information Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie L","family":"Stabi","sequence":"additional","affiliation":[{"name":"Katie L Stabi PharmD BCPS, Drug Information Specialist, Department of Pharmacy, Drug Information Center, Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,5,28]]},"reference":[{"key":"bibr1-aph.1R742","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.11.12852"},{"key":"bibr2-aph.1R742","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.088"},{"key":"bibr3-aph.1R742","unstructured":"3. Centers for Disease Control and Prevention. Herpes zoster. www.cdc.gov\/shingles\/hcp\/clinical-overview.html#complications (accessed 2013 Apr 7)."},{"key":"bibr4-aph.1R742","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.74.6.401"},{"key":"bibr5-aph.1R742","volume-title":"Product information. Pneumovax (pneumococcal vaccine)","year":"2011"},{"key":"bibr6-aph.1R742","unstructured":"6. Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5934a3.htm (accessed 2013 Apr 7)."},{"key":"bibr7-aph.1R742","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"bibr8-aph.1R742","volume-title":"Product information. Zostavax (zoster vaccine)","year":"2011"},{"key":"bibr9-aph.1R742","unstructured":"9. FDA news release. FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age. www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm248390.htm (accessed 2013 Apr 7)."},{"key":"bibr10-aph.1R742","unstructured":"10. Centers for Disease Control and Prevention. Herpes zoster vaccination for health care professionals. www.cdc.gov\/vaccines\/vpd-vac\/shingles\/hcp-vaccination.htm (accessed 2013 Apr 7)."},{"key":"bibr11-aph.1R742","unstructured":"11. Centers for Disease Control and Prevention. Adult vaccination coverage\u2014United States 2010. www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6104a2.htm (accessed 2013 Apr 7)."},{"key":"bibr12-aph.1R742","first-page":"S1","volume":"57","author":"Schaffner W","year":"2008","journal-title":"J Fam Pract"},{"issue":"2","key":"bibr13-aph.1R742","first-page":"6","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR"},{"key":"bibr14-aph.1R742","unstructured":"14. Centers for Disease Control and Prevention. Guidelines for spacing the administration of live and killed antigens. http:\/\/wonder.cdc.gov\/wonder\/prevguid\/p0000348\/p0000348.asp#Table6 (accessed 2013 Apr 7)."},{"key":"bibr15-aph.1R742","unstructured":"15. Vaccines, blood, & biologics. December 18, 2009, approval letter Zostavax. www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm195993.htm (accessed 2013 Apr 7)."},{"key":"bibr16-aph.1R742","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.018"},{"key":"bibr17-aph.1R742","unstructured":"17. Food and Drug Administration. Zostavax (zoster vaccine live) suspension for subcutaneous injection. Detailed view: safety labeling changes approved by the FDA center for biologics evaluation and research (CBER)\u2014March 2011 and January 2010 www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm200862.htm (accessed 2013 Apr 7)."},{"key":"bibr18-aph.1R742","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.046"},{"key":"bibr19-aph.1R742","unstructured":"19. Centers for Disease Control and Prevention. Herpes zoster vaccination for health care professionals. www.cdc.gov\/vaccines\/vpd-vac\/shingles\/hcp-vaccination.htm (accessed 2013 Apr 1)."},{"key":"bibr20-aph.1R742","doi-asserted-by":"publisher","DOI":"10.1086\/528696"},{"key":"bibr21-aph.1R742","doi-asserted-by":"publisher","DOI":"10.1086\/605611"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1R742","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:00Z","timestamp":1777374780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1R742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,28]]},"references-count":21,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1345\/aph.1R742"],"URL":"https:\/\/doi.org\/10.1345\/aph.1r742","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,28]]}}}